Rallybio Corporation (RLYB)
| Market Cap | 77.55M +556.2% |
| Revenue (ttm) | 858,000 +34.9% |
| Net Income | -8.98M |
| EPS | -1.59 |
| Shares Out | 5.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,829 |
| Open | 15.15 |
| Previous Close | 14.56 |
| Day's Range | 14.38 - 15.15 |
| 52-Week Range | 2.16 - 15.31 |
| Beta | -1.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 19, 2026 |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ... [Read more]
Financial Performance
In 2025, Rallybio's revenue was $858,000, an increase of 34.91% compared to the previous year's $636,000. Losses were -$8.98 million, -84.46% less than in 2024.
Financial StatementsNews
Rallybio, Candid Therapeutics announce merger agreement
Rallybio (RLYB) and Candid Therapeutics announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. Upon completion of the...
Rallybio Transcript: M&A announcement
The merger creates a leading TCE therapeutics company for autoimmune diseases, combining robust pipelines and over $500 million in capital to advance multiple candidates into late-stage clinical trials. The combined entity aims for global leadership and accelerated development timelines.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a lead...
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Corp trading halted, news pending
19:50 EST Rallybio (RLYB) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing ...
Rallybio announces reverse 1-for-8 stock split
Rallybio (RLYB) Corporation will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restate...
Rallybio Announces Reverse Stock Split of Common Stock
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an ...
Rallybio Transcript: EGM 2026
Stockholders approved an amendment for a reverse stock split at a ratio between 1:5 and 1:20, with a quorum of 82.81% present. Final results will be disclosed in a Form 8-K within four business days.
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio completes dosing of first cohort in RLYB116 study
Rallybio (RLYB) announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s once-weekly, small volume, su...
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was triggered by the initiation of additional preclinical ...
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Rallybio stock soared on Tuesday after the company reached an agreement with Recursion Pharmaceuticals.
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphata...
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
Recursion (RXRX) acquired Rallybio’s (RLYB) full interest in their joint ENPP1 inhibitor program, REV102, and an associated backup molecule for the treatment of hypophosphatasia, or HPP, a rare and de...
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio initiates dosing in RLYB116 study
Rallybio (RLYB) announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s innovative, once-weekly, small volume, subcutaneous...
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio reports Q1 EPS (21c), consensus (28c)
“We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe that data from this study will demonstrate RLYB116’s potential to be a best-in-...
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Transcript: The Citizens JMP Life Sciences Conference 2025
RLYB212 was discontinued due to clinical limitations, shifting focus to RLYB116, a novel C5 inhibitor targeting rare diseases like APS, with adaptive clinical trials and data readouts expected in Q3 and Q4. Preclinical ENPP1 inhibitor data and financial updates are also anticipated soon.
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio downgraded to Hold from Buy at JonesResearch
JonesResearch analyst Catherine Novack downgraded Rallybio (RLYB) to Hold from Buy without a price target after the company announced discontinuation of lead asset RLYB212 in fetal and neonatal alloim...